Steve Hurly brings nearly two decades of leadership experience in the life sciences industry. He served as President and Chief Executive Officer of Sesen Bio, a NASDAQ listed late stage oncology firm. Prior he served as the President and Chief Executive Officer of Viventia Bio Inc., a specialty pharmaceutical company acquired by Sesen Bio Inc in September 2016. Steve has more than 15 years of experience in the investment banking business. He has served on the board of directors of PHusis Therapeutics Inc., a private targeted small molecule therapeutics company, since May 2011. Previously, he was the Chief Executive Officer of Burrill & Co.’s Merchant Banking Division, a finance business for life science companies. He was also the head of the Life Sciences Investment Banking Practice at Boenning & Scattergood, a securities asset management and investment banking firm. He graduated from Swarthmore College with a B.A. degree in Engineering and earned an M.B.A. from the University of Chicago.
Ton Adang worked at several biotech companies and at Merck/MSD, Schering-Plough and Organon in research and development positions with increasing responsibilities. He held leadership positions in the Lead Discovery Unit and in project management, developing a product through FDA approval and targeting new indications like breast cancer, osteoporosis as well as working with human vaccines, biosimilars and in immune oncology. He received his PhD from the University of Leiden at the Divisions of Bio-Pharmaceutical Sciences and Bio-Organic Chemistry.
Amy Garabedian has extensive global and diversified legal and team building experience. During her more than 15 years practicing law, she has advised pharmaceutical & biotech companies from start-ups to multi-national public companies on the complex legal issues facing industry today. Ms. Garabedian most recently served as associate general counsel of Spark Therapeutics (Roche), where she served as a strategic and innovative advisor, playing an instrumental role in the successful U.S. launch of the first gene therapy for a genetic disease, led key business development transactions, and enabled pre-clinical, clinical and commercial product development. Earlier in her career, Ms. Garabedian held positions of increasing responsibility at Sandoz (Novartis) and as a business and finance attorney at Ballard Spahr LLP. She holds a B.S. in genetics and developmental biology from Penn State University, a M.S. in regulatory affairs from Temple University and a J.D. from Widener University Delaware School of Law.
Paul Parren is an expert in antibody research, translational science and drug development. He is a professor of molecular immunology at the Leiden University Medical Center. Previously, he served as Genmab’s head of preclinical development and research and he was an Associate Professor at The Scripps Research Institute in La Jolla, CA. He invented and developed the approved therapeutic antibodies ofatumumab (Arzerra) and daratumumab (DARZALEX) and clinically validated antibody platform technologies for generating bispecific and enhanced-function antibodies. He contributed to preclinical development of 9 further antibodies in various stages of clinical development. He is a board member of The Antibody Society. He received his PhD from the University of Amsterdam (1992).
Edward F. Smith has more than 20 years of executive finance and operational leadership experience in publicly traded biotechnology companies from early stage through commercial stage. Throughout his career, he has raised hundreds of millions of dollars from IPOs, follow-on equity raises, private placements, convertible securities, and debt issuances. Prior to Lava, Mr. Smith served as CFO of Marinus Pharmaceuticals, Inc., CFO of PolyMedix, Inc., and executive director of finance at InKine Pharmaceutical Company, Inc., where he assisted with the acquisition of the company by Salix Pharmaceuticals, Inc. Earlier in his career, he held various positions of increasing responsibility in public accounting, most recently in the audit practice at Deloitte & Touche, LLP. Mr. Smith is currently a member of the board of directors at Benitec Biopharma, Inc., a development-stage biotechnology company focused on the advancement of novel genetic medicines. Mr. Smith holds a B.S. in business administration from the University of Hartford and was licensed as a Certified Public Accountant in Pennsylvania.
Hans van der Vliet is a professor medical oncology at the Amsterdam UMC, location VUmc. He received his MD from the University of Amsterdam in 1998 and his PhD (cum laude) and internal medicine specialization in medical oncology from the VU University in Amsterdam. He performed post-doctoral research at the Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School.
Benjamin Winograd has longstanding experience in leading drug development programs in Hematology and Oncology at companies including Bristol-Myers Squibb, Pharmacia, Schering-Plough, and Celgene. Most recently he was Clinical R&D Therapeutic Area Head for Multiple Myeloma at Celgene where he led landmark studies resulting in the registration of lenalidomide (Revlimid) and pomalidamide (Pomalyst/Imnovid). Prior to that, he was instrumental in early and late development, registration and launching of cancer therapeutics including paclitaxel (TAXOL), irinotecan (Camptosar), exemestane (Aromasin), epirubicin (ELLENCE), and temozolomide (Temodar). He received his MD and PhD from the Technical University of Munich, Germany, and began his career as part of the EORTC Cooperative Group at the VU University in Amsterdam.